Overview

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

Status:
Terminated

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

To provide efficacy and safety data comparing two dosing schedules of Tobramycin Inhalation Powder (TIP) for the treatment of pulmonary Pseudomonas aeruginosa in patients with cystic fibrosis.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Tobramycin